摘要
目的:评价多烯磷脂酰胆碱联合非诺贝特治疗非酒精性脂肪肝炎(non-alcoholic fatty hepatitis,NASH)的疗效及其安全性.方法:124例非酒精性脂肪肝患者随机分为治疗组(45例)和对照1组(43例)、对照2组(36例),治疗组应用多烯磷脂酰胆碱胶囊联合非诺贝特治疗12 wk,对照1组口服非诺贝特和肌苷治疗12 wk,对照2组口服多烯磷脂酰胆碱胶囊,观察治疗前后3组患者症状及血脂、肝功能及肝脏超声影像变化.结果:治疗12 wk,治疗组有效率为86.7%,对照1组有效率为53.5%,对照2组有效率为8 8.9%,治疗组在改善患者临床症状、肝功能均优于对照1组,差异均有统计学意义(P<0.05);血脂方面治疗组优于对照2组,差异有统计学意义(P<0.05).结论:多烯磷脂酰胆碱联合非诺贝特治疗NASH是安全有效的.
AIM： To investigate the efficacy and safety of polyene phosphatidylcholine combined with fenofibrate capsules in the treatment of nonalco- holic steatohepatitis （NASH）, METHODS： A total of 124 patients with NASH were selected and divided randomly into two groups： a treatment group and two control groups. The treatment group received polyene phosphatidylcholine combined with fenofibrate capsules （n = 45） for 12 wk, while the two control groups received fenofibrate capsules and inosine （n = 43） and polyene phosphatidylcholine alone （n = 36） for the same duration, respectively. The levels of serum transaminase, clinical symptoms, blood lipids and B-mode ultrasonic imaging findings before and after treatment were com- pared between groups. RESULTS： The levels of serum transaminase, clinical symptoms, blood lipids and B-mode ul- trasonic imaging findings improved obviously after treatment. The response rates were 86.7%, 53.5% and 88.9% in the treatment group and the two control groups, respectively. There were significant differences between the three groups in the improvement of clinical symptoms, liver function and blood lipids （P 〈 0.05 for all）. CONCLUSION： Treatment of NASH with feno- fibrate capsules combined with polyene phos- phatidylcholine is safe and effective.
出处
《世界华人消化杂志》
CAS
北大核心
2014年第3期429-433,共5页
World Chinese Journal of Digestology
